**Table 3** Adverse events compared with GOG first-line [32] and second-line [33] studies, all grades, by number of patients experiencing the event

| Adverse event | Grade by National Cancer Institution Common Toxicity Criteria version 3.0 | | | | | |
|---|---|---|---|---|---|---|
| | 0 | 1 | 2 | 3 | 4 | 3/4 (%) |
| **Neutropenia** | | | | | | |
| This study | 0 | 0 | 3 | 2 | 5 | 70.0 |
| GOG first-line | 27 | 2 | 6 | 2 | 5 | 16.7 |
| GOG second-line | 19 | 9 | 10 | 6 | 4 | 20.8 |
| **Anemia** | | | | | | |
| This study | 5 | 1 | 2 | 1 | 1 | 20.0 |
| GOG first-line | 0 | 7 | 25 | 10 | 0 | 23.8 |
| GOG second-line | 4 | 6 | 26 | 10 | 2 | 25.0 |
| **Thrombocytopenia** | | | | | | |
| This study | 5 | 1 | 1 | 1 | 2 | 30.0 |
| GOG first-line | 9 | 22 | 5 | 4 | 2 | 14.3 |
| GOG second-line | 8 | 11 | 10 | 14 | 5 | 39.6 |
| **RBC transfusion** | | | | | | |
| This study | 10 | 0 | 0 | 0 | 0 | 0.0 |
| GOG second-line | 24 | 0 | 0 | 24 | 0 | 50.0 |
| **Platelet transfusion** | | | | | | |
| This study | 10 | 0 | 0 | 0 | 0 | 0.0 |
| GOG second-line | 42 | 0 | 0 | 6 | 0 | 12.5 |
| **Nausea/vomiting** | | | | | | |
| This study | 3 | 7 | 0 | 0 | 0 | 0.0 |
| GOG second-line | 29 | 12 | 6 | 0 | 1 | 2.1 |
| **Anorexia** | | | | | | |
| This study | 3 | 7 | 0 | 0 | 0 | 0.0 |
| GOG first-line | 12 | 12 | 12 | 5 | 1 | 14.3 |
| GOG second-line | 18 | 15 | 12 | 2 | 1 | 6.3 |
| **Liver dysfunction** | | | | | | |
| This study | 5 | 3 | 1 | 1 | 0 | 10.0 |
| GOG first-line | 35 | 7 | 0 | 0 | 0 | 0.0 |
| GOG second-line | 38 | 6 | 3 | 1 | 0 | 2.1 |
| **Pulmonary** | | | | | | |
| This study | 10 | 0 | 0 | 0 | 0 | 0.0 |
| GOG first-line | 32 | 6 | 3 | 0 | 1 | 2.4 |
| GOG second-line | 36 | 4 | 4 | 3 | 1 | 8.3 |
| **Fatigue** | | | | | | |
| This study | 3 | 3 | 4 | 0 | 0 | 0.0 |
| GOG first-line | 11 | 15 | 9 | 7 | 0 | 16.7 |
| GOG second-line | 40 | 2 | 5 | 1 | 0 | 2.1 |
| **Alopecia** | | | | | | |
| This study | 6 | 4 | 0 | 0 | 0 | 0.0 |
| GOG second-line | 21 | 1 | 26 | 0 | 0 | 0.0 |
| **Infection** | | | | | | |
| This study | 9 | 0 | 0 | 1 | 0 | 10.0 |
| GOG first-line | 30 | 3 | 8 | 1 | 0 | 2.4 |
| GOG second-line | 43 | 2 | 1 | 2 | 0 | 4.2 |
| **Genitourinary** | | | | | | |
| This study | 9 | 0 | 0 | 1 | 0 | 10.0 |
| GOG first-line | 36 | 3 | 3 | 0 | 0 | 0.0 |
| GOG second-line | 45 | 2 | 1 | 0 | 0 | 0.0 |

**Table 3** continued

| Adverse event | Grade by National Cancer Institution Common Toxicity Criteria version 3.0 | | | | | |
|---|---|---|---|---|---|---|
| | 0 | 1 | 2 | 3 | 4 | 3/4 (%) |
| Neurotoxicity | | | | | | |
| This study | 10 | 0 | 0 | 0 | 0 | 0.0 |
| GOG first-line | 32 | 7 | 2 | 1 | 0 | 2.4 |
| GOG second-line | 26 | 15 | 7 | 0 | 0 | 0.0 |
| Allergic reaction | | | | | | |
| This study | 10 | 0 | 0 | 0 | 0 | 0.0 |
| GOG first-line | 33 | 5 | 3 | 1 | 0 | 2.4 |
| GOG second-line | 46 | 0 | 2 | 0 | 0 | 0.0 |

*RBC* red blood cell, *GOG* Gyencologic Oncology Group

[34]; DCR: 77 % [33], 62 % [34]; OS: 14.7 [33], 16.1 months [34]; and durations of objective response: 9+ [33], 6 months [34]). Thus, we conclude that 900 mg/m$^2$ gemcitabine plus dose-reduced docetaxel (70 mg/m$^2$)was highly efficacious in treated and untreated Japanese patients with advanced or recurrent LMS and UES (Table 1).

Toxicity

The toxicities associated with treatment were mainly bone marrow suppression: neutropenia grade 3 in 20 %, grade 4 in 50 %; anemia grade 3 in 10 %, grade 4 in 10 %; thrombocytopenia grade 3 in 10 %, grade 4 in 20 %. In the GOG second-line study, which employed G-CSF for 7 days, the toxicities associated with treatment were mainly uncomplicated myelosuppression: thrombocytopenia grade 3 (29 %), grade 4 (10.4 %); neutropenia grade 3 (12.5 %), grade 4 (8.3 %); and anemia grade 3 (20.8 %), grade 4 (4.2 %) [33]. Although neutropenia (grade 3 in 12.5 %, grade 4 in 8.3 %) was less frequent than that in this study (grade 3 in 20 %, grade 4 in 50 %), we had no episodes of life-threatening neutropenia. In the GOG first-line study, grade 3/4 myelosuppression was less frequent than that in the second-line study, with neutropenia grade 3 in 5 %, grade 4 in 12 %; anemia grade 3 in 24 %; and thrombocytopenia grade 3 in 9.5 %, grade 4 in 5 % [34]. In the GOG second-line study, the median number of cycles was 5.5, with a range extending up to 22 cycles [33] and in the first-line study, half of patients received more than 6 cycles of therapy [34]. In our study, among the total 50 cycles, 22 cycles (44 %) were for 4 patients who required the use of G-CSF (half the dose of and shorter term than the GOG trials). No grade 4 febrile neutropenia was observed. The median number of treatment cycles per patient was 5 (range 2–18 cycles), fewer than in the GOG second-line (5.5) [33] and first-line (6+) [34] studies. This was expected because 3 SD patients in the present study elected to change the chemotherapeutic regimen after the third cycle. These data support the suggestion that gemcitabine plus docetaxel without prophylactic G-CSF support is a tolerable regimen, and should be considered as a treatment option for advanced or recurrent LMS and UES in Japanese patients.

Active study

Further research is required to assess whether molecularly targeted therapies are effective in LMS and UES. In a phase I study in which gemcitabine, docetaxel, and bevacizumab (5 mg/kg) were all given concurrently every 2 weeks to patients with previously untreated soft tissue sarcoma (LMS, 5 patients; angiosarcoma, 3 patients; other histologies, 19 patients), 11 of 25 assessable patients had objective responses, including three with a complete remission [35]. The results of a randomized phase III trial of docetaxel and gemcitabine plus G-CSF with bevacizumab versus docetaxel and gemcitabine plus G-CSF with placebo in the treatment of advanced LMS (GOG0250) are awaited.

References

1. Major FJ, Blessing JA, Silverberg SG et al (1993) Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer 71:1702–1709
2. Oláh KS, Dunn JA, Gee H (1992) Leiomyosarcomas have a poorer prognosis than mixed mesodermal tumours when adjusting for known prognostic factors: the result of a retrospective study of 423 cases of uterine sarcoma. Br J Obstet Gynaecol 99:590–594

🖄 Springer

3. Harlow BL, Weiss NS, Lofton S (1986) The epidemiology of sarcomas of the uterus. J Natl Cancer Inst 76:399–402

4. Akahira J, Tokunaga H, Toyoshima M et al (2006) Prognoses and prognostic factors of carcinosarcoma, endometrial stromal sarcoma and uterine leiomyosarcoma: a comparison with uterine endometrial adenocarcinoma. Oncology 71:333–340

5. The National Comprehensive Cancer Network (2013) NCCN Clinical Practice Guidelines in Oncology. Uterine neoplasms. In: version 1. Available via DIALOG. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site

6. Levenback CF, Tortolero-Luna G, Pandey DK et al (1996) Uterine sarcoma. Obstet Gynecol Clin North Am 23:457–473

7. Omura GA, Major FJ, Blessing JA et al (1983) A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer 52:626–632

8. Sutton G, Blessing JA, Malfetano JH (1996) Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 62:226–229

9. Sutton GP, Blessing JA, Barrett RJ et al (1992) Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Am J Obstet Gynecol 166:556–559

10. Look KY, Sandler A, Blessing JA et al (2004) Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study. Gynecol Oncol 92:644–647

11. Garcia-Carbonero R, Supko JG, Maki RG et al (2005) Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol 23:5484–5492

12. Amant F, Coosemans A, Renard V et al (2009) Clinical outcome of ET-743 (Trabectedin; Yondelis) in high-grade uterine sarcomas: report on five patients and a review of the literature. Int J Gynecol Cancer 19:245–248

13. Anderson S, Aghajanian C (2005) Temozolomide in uterine leiomyosarcomas. Gynecol Oncol 98:99–103

14. Thigpen JT, Blessing JA, Wilbanks GD (1986) Cisplatin as second-line chemotherapy in the treatment of advanced or recurrent leiomyosarcoma of the uterus. A phase II trial of the Gynecologic Oncology Group. Am J Clin Oncol 9:18–20

15. Thigpen JT, Blessing JA, Homesley HD et al (1985) Phase II trial of piperazinedione in patients with advanced or recurrent uterine sarcoma. A Gynecologic Oncology Group study. Am J Clin Oncol 8:350–352

16. Thigpen JT, Blessing JA, Beecham J et al (1991) Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study. J Clin Oncol 9:1962–1966

17. Sutton G, Blessing J, Hanjani P et al (2005) Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 96:749–752

18. Thigpen T, Blessing JA, Yordan E et al (1996) Phase II trial of etoposide in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 63:120–122

19. Rose PG, Blessing JA, Soper JT et al (1998) Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol 70:267–271

20. Sutton G, Blessing JA, Ball H (1999) Phase II trial of paclitaxel in leiomyosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol 74:346–349

21. Gallup DG, Blessing JA, Andersen W et al (2003) Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol 89:48–51

22. Miller DS, Blessing JA, Kilgore LC et al (2000) Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group Study. Am J Clin Oncol 23:355–357

23. Smith HO, Blessing JA, Vaccarello L (2002) Trimetrexate in the treatment of recurrent or advanced leiomyosarcoma of the uterus: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 84:140–144

24. Hensley ML, Sill MW, Scribner DR et al (2009) Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol 115:460–465

25. McMeekin DS, Sill MW, Benbrook D et al (2007) A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study. Gynecol Oncol 105:508–516

26. Eisenhauer E (1995) Docetaxel: current status and future prospects. J Clin Oncol 13:2865–2868

27. Huang P, Chubb S, Hertel LW et al (1991) Action of 2',2'-difluorodeoxycytidine on DNA synthesis. Cancer Res 51:6110–6117

28. Ebeling P, Eisele L, Schuett P et al (2008) Docetaxel and gemcitabine in the treatment of soft tissue sarcoma—a single-center experience. Onkologie 31:11–16

29. Ferraresi V, Ciccarese M, Cercato MC et al (2008) Gemcitabine at fixed dose-rate in patients with advanced soft-tissue sarcomas: a mono-institutional phase II study. Cancer Chemother Pharmacol 63:149–155

30. Maki RG, Wathen JK, Patel SR et al (2007) Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol 25:2755–2763

31. Hensley ML, Maki R, Venkatraman E et al (2002) Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 20:2824–2831

32. Hensley ML, Ishill N, Soslow R et al (2009) Adjuvant gemcitabine plus docetaxel for completely resected stages I–IV high grade uterine leiomyosarcoma: results of a prospective study. Gynecol Oncol 112:563–567

33. Hensley ML, Blessing JA, Degeest K et al (2008) Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol 109:323–328

34. Hensley ML, Blessing JA, Mannel R et al (2008) Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol 109:329–334

35. Verschraegen CF, Arias-Pulido H, Lee SJ et al (2012) Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen. Ann Oncol 23:785–790

36. Muss HB, Bundy B, DiSaia PJ et al (1985) Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group). Cancer 55:1648–1653

37. Pautier P, Floquet A, Penel N et al (2012) Randomized multicenter and stratified Phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study). Oncologist. 17:1213–1220

38. Hannigan EV, Freedman RS, Elder KW (1983) Treatment of advanced uterine sarcoma with vincristine, actinomycin D, and cyclophosphamide. Gynecol Oncol 15:224–229

39. Edmonson JH, Blessing JA, Cosin JA et al (2002) Phase II study of mitomycin, doxorubicin, and cisplatin in the treatment of advanced uterine leiomyosarcoma: a Gynecologic Oncology Group study. Gynecol Oncol 85:507–510

40. Long HJ, Blessing JA, Sorosky J (2005) Phase II trial of dacarbazine, mitomycin, doxorubicin, and cisplatin with sargramostim in uterine leiomyosarcoma: a Gynecologic Oncology Group study. Gynecol Oncol 99:339–342

41. Leyvraz S, Zweifel M, Jundt G et al (2006) Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas. Ann Oncol 17:646–651

# Taxane-sensitivity of ovarian carcinomas previously treated with paclitaxel and carboplatin

Yutaka Ueda · Takayuki Enomoto · Shinya Matsuzaki ·
Eiji Kobayashi · Toshihiro Kimura · Kiyoshi Yoshino ·
Masami Fujita · Tateki Tsutsui · Tadashi Kimura

## Abstract

*Purpose* The aim of the present study was to investigate, in ovarian carcinoma cases, the predictive association between the treatment-free interval (TFI) after an initial paclitaxel plus carboplatin (TC) therapy and the subsequent effectiveness of a second-line taxane-containing chemotherapy.
*Methods* Patients with a TFI < 6 months from the first-line TC therapy were treated with a combination chemotherapy using docetaxel and irinotecan; patients with a TFI ≥ 6 months were retreated with the same regimen as the initial TC therapy. The clinical data of these patients were retrospectively analyzed for this study.
*Results* The response rate of those with a TFI equal to 6–12 months was greater than that of those with a TFI < 6 months ($p = 0.014$) and less than that of those with a TFI > 12 months ($p = 0.012$). The progression-free survival of the cases with TFI equal to 6–12 months was longer than that of those with TFI < 6 months ($p = 0.012$) and shorter than that of those with TFI > 12 months ($p = 0.0011$). Overall survival of cases with a TFI equal to 6–12 months was longer than that of those with TFI < 6 months ($p = 0.012$) and shorter than that of those with TFI > 12 months ($p = 0.0005$).
*Conclusions* The effectiveness of using a second-line taxane-containing chemotherapy was shown to be predictable by the TFI after the first-line taxane-containing chemotherapy, implying that the theory of 'taxane-sensitivity' may be applied for second-line chemotherapy in the same way as that of 'platinum-sensitivity'.

**Abbreviations**

| | |
|---|---|
| CR | Complete response |
| OS | Overall survival |
| PD | Progressive disease |
| PFS | Progression-free survival |
| PR | Partial response |
| RR | Responsive rate |
| SD | Stable disease |
| TFI | Treatment-free interval |
| TC | Paclitaxel and carboplatin |

## Introduction

Ovarian cancer is the ninth most common cancer in US women, yet causes more deaths than any other cancer of the female reproductive system. The preferred primary management of ovarian carcinoma is surgical debulking followed by adjuvant TC (paclitaxel and carboplatin) therapy. Ovarian carcinomas respond well to first-line TC therapy. However, even though the initial response rate to platinum-based chemotherapy can be 70–80 %, most of those patients with advanced disease will eventually relapse and die of a chemo-resistant disease [1–3].

For a relapsed disease, a second-line chemotherapy is usually attempted. The probability of a response to the second-line chemotherapy can be estimated by the treatment-free interval (TFI) after the initial platinum-based chemotherapy. The second-line platinum chemotherapy

Y. Ueda (✉) · T. Enomoto (✉) · S. Matsuzaki · E. Kobayashi · T. Kimura · K. Yoshino · M. Fujita · T. Tsutsui · T. Kimura
Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, 2-2, Yamadaoka,
Suita, Osaka 565-0871, Japan
e-mail: ZVF03563@nifty.ne.jp

🖄 Springer

was considered to be more likely to be efficacious the longer the TFI was. Relapsing cases with a TFI < 6 months after the first-line platinum-based chemotherapy were considered likely to be 'platinum-resistant'; on the other hand, those cases with a TFI ≥ 6 months were considered likely to still be 'platinum-sensitive' [4–6]. Regimens other than repeating the initial chemotherapy were recommended for the quickly relapsing cases; however, patients with a TFI ≥ 6 months had a better chance of responding well either to a rechallenge with the initial platinum-based first-line treatment (such as TC therapy) or to certain other drugs. In the 'platinum-sensitive' cases, a combination chemotherapy using liposomal doxorubicin and carboplatin was demonstrated to be more effective than TC therapy [7]. Gemcitabine plus carboplatin was also shown to be more effective for 'platinum-sensitive' cases than carboplatin alone [8].

Among the 'platinum-sensitive' cases, those with a TFI of 6–12 months still exhibited a relatively worse response to second-line chemotherapy using carboplatin after a standard first-line TC therapy than those with a TFI of ≥12 months and were considered to be 'partially sensitive' cases [6]. For those ovarian carcinoma patients with 6–12 months of TFI after the first-line TC therapy, a combination chemotherapy of liposomal doxorubicin and carboplatin was shown to provide a better prognosis [9].

These findings were based on the theory of 'platinum-sensitivity'. To our knowledge, there has been little similar discussion related to relapse and 'taxane-sensitivity'. In the present study, the effectiveness of a combination chemotherapy using taxane with irinotecan or carboplatin as a second-line therapy after initial TC therapy was investigated to provide evidence for predicting 'taxane-sensitivity' in relapsing tumors.

## Materials and methods

### Patients

During the 7-year study period of 2002–2009, we conducted a prospective phase I/II study of a combination chemotherapy using docetaxel and irinotecan for TC-refractory or TC-resistant ovarian carcinoma cases (GOGO-OV2) (to be described in detail elsewhere). In brief, docetaxel and irinotecan were administered on day 1 and day 8, every 3 weeks, for the patients whose TFI was shorter than 6 months from the first-line TC therapy (175 mg/m$^2$ for paclitaxel and AUC 5 for carboplatin, every 3 weeks). In a phase I component, the recommended dose was determined to be 30 mg/m$^2$ (day 1 and day 8) for docetaxel and 50 mg/m$^2$ (day 1 and day 8) for irinotecan. On the other hand, the patients whose TFI was equal to or

longer than 6 months from the first-line TC therapy were again treated with the same regimen as the initial TC therapy.

In the present study, the cases with a TFI < 6 months that were treated with a combination chemotherapy using docetaxel and irinotecan in a phase II component and the patients with a TFI ≥ 6 months who were treated with TC therapy were retrospectively analyzed.

## Methods

In order to evaluate the therapeutic effect of the second-line chemotherapy, we used the previously described standard criteria from the World Health Organization [10] and others [11–13]. The tumors were assessed with a CT scan and/or MRI at baseline and every three treatment courses thereafter. A complete response (CR) was defined as the disappearance of all known disease, determined by two observations no less than 4 weeks apart. Partial response (PR) was defined as a 50 % or more reduction in the summed products of the two largest perpendicular dimensions of bidimensionally measurable lesions, for at least 4 weeks. Stable disease (SD) was defined as a less than 50 % decrease, or a less than 25 % increase, in tumor size, with no new detectable lesions. Progressive disease (PD) was defined as a greater than 25 % increase in tumor size, or as the appearance of new lesions.

Progression-free survival (PFS) was measured from the date of the last administration of chemotherapy to the date of the radiologic or pathologic denoted relapse, or to the date of the last follow-up. Overall survival (OS) was defined as the period from the start of chemotherapy to the patient's death, or to the date of the last follow-up, as previously described. TFI was defined as the period between the last administration of first-line chemotherapy and the initiation of the second-line chemotherapy, as previously described [14].

### Statistical analysis of effect of second-line chemotherapy

Associations between the TFI and the patients' characteristics, including age, histology and initial stage, were analyzed by Pearson's Chi-square test. Association between sensitivity to second-line chemotherapy and TFI was analyzed by Fisher's exact test. PFS and OS curves determined by TFI were constructed using the Kaplan–Meier method and were evaluated for statistical significance by the log-rank test. The Bonferroni correction was used to assess differences among the three groups, and a value of $p < 0.017$ was considered statistically significant.

## Results

### Clinical characteristics of the study cases

During the 7-year study period, 145 patients underwent a second-line chemotherapy against a refractory or resistant disease, after having first received an adjuvant or salvage first-line chemotherapy using a TC regimen. The clinico-pathological characteristics of these patients are shown in Table 1. Sixty-two patients with a TFI < 6 months received a combination chemotherapy of docetaxel and irinotecan; 36 patients with TFI = 6–12 months and 47 patients with TFI > 12 months were treated with this TC regimen.

### Outcome of the patients after second-line chemotherapy

Only nine (15 %) of 62 patients whose TFI was shorter than 6 months exhibited sensitivity to a second-line chemotherapy using docetaxel and irinotecan; however, 13 (36 %) of 36 patients whose TFI was 6–12 months and 30 (64 %) of 47 cases >12 months responded to second-line TC therapy (Table 2).

The longer the TFI was, the higher the response rate was. The response rate of the cases with TFI = 6–12 months was significantly longer than that of those with TFI < 6 months, and that of those with TFI > 12 months

was longer than that of those with TFI = 6–12 months ($p = 0.014$ and $p = 0.012$, respectively). These associations were statistically significant (Fisher's exact test with Bonferroni's correction).

### PFS and OS after second-line chemotherapy, by TFI

Differences by TFI in effectiveness of second-line chemotherapy regimens were investigated. The median PFS was 5 months (2–17 months) for 62 patients with TFI < 6 months, 8 months (1–65 months) for 36 patients with TFI = 6–12 months and 13 months (3–83 months) for 47 patients with TFI > 12 months. The longer the TFI was, the longer the PFS rate was. These associations were statistically significant ($p = 0.012$ and $p = 0.0011$, respectively) (log-rank test with Bonferroni's correction) (Fig. 1).

The median OS was 15 months (3–50 months) for 62 patients with TFI < 6 months, was 24 months (3–65 months) for 36 patients with TFI = 6–12 months and was 37 months (8–83 months) for 47 patients with TFI > 12 months. The longer the TFI was, the longer the PFS rate was. These associations were statistically significant ($p = 0.012$ and $p = 0.0005$, respectively) (log-rank test with Bonferroni's correction) (Fig. 2).

## Conclusions

Chemotherapy plays an extremely important role in the treatment for ovarian carcinoma. Platinum has long been a key drug for ovarian carcinoma, and now a combination chemotherapy of platinum and taxane, especially TC therapy, is the gold standard for first-line regimens. For relapsed diseases, a second-line chemotherapy is usually performed. The effectiveness of this second-line chemotherapy was known to be associated with the TFI from the platinum-based first-line chemotherapy. The early relapsing cases, those with a TFI less than 6 months, were considered likely to be 'platinum-resistant', those with a TFI of 6–12 months were considered as 'partially sensitive' to platinum, and those with TFI ≥ 12 months were considered to be 'platinum-sensitive' [4–6].

Because platinum has been effectively used in the first-line chemotherapy, 'platinum-sensitivity' has often been used as the most important predictive factor of efficacy of second-line chemotherapy. However, taxane drugs, including paclitaxel and docetaxel, were also shown to be effective for ovarian carcinoma [15–17], and a combination TC therapy is currently regarded as a standard therapy. Under the specific circumstance that a TC therapy is used as the first-line chemotherapy, sensitivity not only to platinum but also to taxane may be a predictive factor for efficacy of the second-line chemotherapy.

**Table 1** Clinical characteristics of the cases

| TFI | <6–12 months | 6–12 months | >12 months | $p$ Value |
|---|---|---|---|---|
| Number | 62 | 36 | 47 | – |
| Age (years) | | | | 0.39 |
| <60 | 39 | 20 | 33 | |
| ≥60 | 3 | 16 | 14 | |
| Histology | | | | 0.08 |
| Serous | 40 | 26 | 34 | |
| Endometrioid | 7 | 5 | 6 | |
| Clear | 8 | 1 | 5 | |
| Mucinous | 6 | 0 | 1 | |
| Others | 1 | 4 | 1 | |
| Initial stage | | | | 0.42 |
| I/II | 12 | 5 | 12 | |
| III/IV | 50 | 31 | 35 | |

Clinical characteristics of the cases with a TFI < 6 months after first-line TC therapy that were treated with a combination chemotherapy using docetaxel and irinotecan, the patients with a TFI = 6–12 months and those with a TFI ≥ 12 months, who were treated with TC therapy again, are shown. Association between TFI and the patients' characteristics, including age, histology and initial stage, was analyzed by Pearson's Chi-square test

*TFI* treatment-free interval

**Table 2** Association between TFI and effectiveness of a second-line chemotherapy using taxane

| Second-line chemotherapy | Docetaxel + irinotecan | Paclitaxel + carboplatin | |
| --- | --- | --- | --- |
| TFI | <6 months | 6–12 months | >12 months |
| CR | 1 | 6 | 4 |
| PR | 8 | 7 | 16 |
| SD | 15 | 10 | 8 |
| PD | 38 | 13 | 9 |
| Response rate (%) | 15 | 36 | 64 |

The response rate of the cases with a TFI = 6–12 months was significantly better than that of those with TFI < 6 months, and that of those with TFI > 12 months was better than that of those with a TFI = 6–12 months ($p = 0.014$ and $p = 0.012$, respectively). These associations were statistically significant (Fisher's exact test with Bonferroni's correction)

*TFI* treatment-free interval, *CR* complete response, *PR* partial response, *SD* stable disease, *PD* progressive disease



**Fig. 1** PFS after second-line chemotherapy by TFI. The PFS of 62 patients with a TFI < 6 months was shorter than that of 36 patients with a TFI = 6–12 months, which was shorter than that of 47 patients with a TFI > 12 months. These associations were statistically significant ($p = 0.012$ and $p = 0.0011$, respectively) (log-rank test, with Bonferroni's correction) *PFS* progression-free survival



**Fig. 2** OS after second-line chemotherapy by TFI. The OS of 62 patients with a TFI < 6 months was shorter than that of 36 patients with a TFI = 6–12 months, which was shorter than that of 47 patients with a TFI > 12 months. These associations were statistically significant ($p = 0.012$ and $p = 0.0005$, respectively) (log-rank test, with Bonferroni's correction) *OS* overall survival

Gronlund et al. [3] showed that retreatment with a TC regimen in the patients with TFI $\geq$ 6 months yielded a high response rate. There was a relative increase in response rates comparing TFI = 6–9 months ($n = 9$), TFI = 9–12 months ($n = 6$) and TFI > 12 months ($n = 22$), but the differences were not statistically significant, probably due to the small sample sizes.

Docetaxel exhibits a response rate of 22.4 % for those diseases which progressed either while undergoing therapy or within 6 months of completing therapy with paclitaxel and platinum [18]. Aravantinos et al. [19] reported that a response rate of 26.8 % was observed by treatment with docetaxel plus vinorelbine in 41 platinum-resistant and paclitaxel-pretreated patients who had a TFI < 6 months. Recently, Fu et al. [20] demonstrated that a PR was obtained by perifosine plus docetaxel in one (5 %) of 21 platinum- and- taxane-resistant or platinum-and-taxane-refractory high-grade ovarian carcinoma cases. Ushijima et al. [21] showed that a combination chemotherapy of docetaxel and irinotecan (the same regimen as in our study) exhibited a response rate of 6.3 % in the ovarian carcinoma cases with a TFI < 6 months (refractory or resistant) from a first-line chemotherapy, with at least two cycles of platinum and/or taxane. Polyzos et al. [22] also showed that six (20 %) of 30 paclitaxel-pretreated patients with likely platinum-resistant (TFI < 6 months) recurrences exhibited complete or partial response to a second-line docetaxel plus irinotecan regimen.

To our knowledge, the effectiveness of using a taxane-containing second-line chemotherapy in those patients previously treated with taxane-containing chemotherapy, especially the highly used gold standard TC therapy, has never been systematically investigated. In the present study, the effectiveness of a second-line combination chemotherapy using taxane with another drug (after a first-line TC therapy) was analyzed to redress that gap in our knowledge.

In the present study, 62 patients with a TFI < 6 months received a combination chemotherapy of docetaxel and irinotecan, and 36 patients with a TFI = 6–12 months and 47 patients with a TFI > 12 months were treated with a TC regimen. We were clearly able to demonstrate a significant association between the TFI after a first-line TC therapy and the response to a second-line chemotherapy containing taxane. The response rate of the cases with TFI = 6–12 months was significantly better than that of those with a TFI < 6 months, and the response rate of those with a TFI > 12 months was better yet than that of those with a TFI = 6–12 months ($p = 0.014$ and $p = 0.012$, respectively).

Moreover, a significant association between TFI after first-line TC therapy and the survival effect of the second-line chemotherapy using taxane with irinotecan, or carboplatin, was also demonstrated. The PFS of the cases with a TFI = 6–12 months was significantly longer than that of those with a TFI < 6 months, and that of those with a TFI > 12 months was longer than that of those with a TFI = 6–12 months ($p = 0.012$ and $p = 0.0011$, respectively). The OS of the cases with a TFI = 6–12 months was significantly longer than that of those with a TFI < 6 months, and that of those with a TFI > 12 months was longer than that of those with a TFI = 6–12 months ($p = 0.012$ and $p = 0.0005$, respectively).

These results imply that effectiveness of second-line taxane-containing chemotherapy is predictable by the TFI after first-line taxane-containing chemotherapy. Second-line regimens might thus be intelligently selected based on the likely 'taxane-sensitivity' of the relapsing tumor.

Paclitaxel and carboplatin therapy is currently used for ovarian carcinoma cases as a standard first-line chemotherapy all over the world. If the theory of 'taxane-sensitivity' can be applied for second-line chemotherapy in the same way as that of 'platinum-sensitivity', a combination chemotherapy of taxane with platinum, and other drugs, including liposomal doxorubicin and gemcitabine, might be effective. Markman et al. [23] showed a 25 % response of weekly paclitaxel even in TC-resistant cases. Weekly administration of taxane may be effective for some 'taxane-resistant' cases.

Our present study provides, for the first time, good evidence that the longer the TFI is after first-line taxane-containing chemotherapy, the more effective the second-line taxane-containing chemotherapy is likely to be, implying the model of 'taxane-sensitivity' may be applied for the second-line chemotherapy in the same way as that of 'platinum-sensitivity'. However, in our study, all the patients received platinum combined with taxane as the first-line chemotherapy, and those with late relapse (>6 months) were treated with a chemotherapy using platinum (carboplatin) combined with taxane. These data may reflect, in some part, platinum-sensitivity phenomenon. Further investigation is still required to establish an idea of 'taxane-sensitivity' and an efficacious strategy for second-line chemotherapy for advanced or recurrent ovarian cancer.

# References

1. McGuire WP, Ozols RF (1998) Chemotherapy of advanced ovarian cancer. Semin Oncol 25:340–348. Review. Erratum in: Semin Oncol. 25:707
2. Ozols RF (1997) Treatment of recurrent ovarian cancer: increasing options–"recurrent" results. J Clin Oncol 15:2177–2180
3. Gronlund B, Høgdall C, Hansen HH, Engelholm SA (2001) Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer. Gynecol Oncol 83:128–134
4. Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Lewis JL Jr (1991) Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9:389–393
5. Harries M, Gore M (2002) Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease. Lancet Oncol 3:537–545
6. Dizon DS, Dupont J, Anderson S, Sabbatini P, Hummer A, Aghajanian C, Spriggs D (2003) Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experience. Gynecol Oncol 91:584–590
7. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey PA, Volgger B, Vergote I, Pignata S, Ferrero A, Sehouli J, Lortholary A, Kristensen G, Jackisch C, Joly F, Brown C, Le Fur N, du Bois A (2010) Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 28:3323–3329
8. Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ, Wagner U, Stähle A, Stuart G, Kimmig R, Olbricht S, Le T, Emerich J, Kuhn W, Bentley J, Jackisch C, Lück HJ, Rochon J, Zimmermann AH, Eisenhauer E, AGO-OVAR, NCIC CTG, EORTC GCG (2006) Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24:4699–4707
9. Rapoport BL, Vorobiof DA, Slabber C, Alberts AS, Hlophe HS, Mohammed C (2009) Phase II study of pegylated liposomal doxorubicin and carboplatin in patients with platinum-sensitive and partially platinum-sensitive metastatic ovarian cancer. Int J Gynecol Cancer 19:1137–1141
10. World Health Organization (1979) WHO handbook of reporting results of cancer treatment no. 48. WHO Offset Publication, Geneva, Switzerland
11. Pectasides D, Xiros N, Papaxoinis G, Pectasides E, Sykiotis C, Koumarianou A, Psyrri A, Gaglia A, Kassanos D, Gouveris P,

Panayiotidis J, Fountzilas G, Economopoulos T (2008) Carboplatin and paclitaxel in advanced or metastatic endometrial cancer. Gynecol Oncol 109:250–254

12. Bartsch R, Wenzel C, Altorjai G, Pluschnig U, Rudas M, Mader RM, Gnant M, Zielinski CC, Steger GG (2007) Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol 25:3853–3858

13. Ueno Y, Enomoto T, Otsuki Y, Sugita N, Nakashima R, Yoshino K, Kuragaki C, Ueda Y, Aki T, Ikegami H, Yamazaki M, Ito K, Nagamatsu M, Nishizaki T, Asada M, Kameda T, Wakimoto A, Mizutani T, Yamada T, Murata Y (2006) Prognostic significance of p53 mutation in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin. Cancer Lett 241:289–300

14. Markman M, Markman J, Webster K, Zanotti K, Kulp B, Peterson G, Belinson J (2004) Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol 22:3120–3125

15. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1–6

16. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B, Paul J, Baron B, Pecorelli S (2000) Randomized intergroup trial of cisplatin–paclitaxel versus cisplatin–cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 92:699–708

17. Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A, Kaye SB, Scottish Gynaecological Cancer Trials Group (2004) Phase III randomized trial of docetaxel–carboplatin versus paclitaxel–carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96:1682–1691

18. Rose PG, Blessing JA, Ball HG, Hoffman J, Warshal D, DeGeest K, Moore DH (2003) A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a gynecologic oncology group study. Gynecol Oncol 88:130–135

19. Aravantinos G, Bafaloukos D, Fountzilas G, Christodoulou C, Papadimitriou C, Pavlidis N, Kalofonos HP, Gogas H, Kosmidis P, Dimopoulos MA (2003) Phase II study of docetaxel–vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer. Ann Oncol 14:1094–1099

20. Fu S, Hennessy BT, Ng CS, Ju Z, Coombes KR, Wolf JK, Sood AK, Levenback CF, Coleman RL, Kavanagh JJ, Gershenson DM, Markman M, Dice K, Howard A, Li J, Li Y, Stemke-Hale K, Dyer M, Atkinson E, Jackson E, Kundra V, Kurzrock R, Bast RC Jr, Mills GB (2012) Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. Gynecol Oncol. 2012 Apr 6 [Epub ahead of print]

21. Ushijima K, Kamura T, Tamura K, Kuzuya K, Sugiyama T, Noda K, Ochiai K (2011) Docetaxel/irinotecan combination chemotherapy in platinum/taxane-refractory and -resistant ovarian cancer: JGOG/WJGOG Intergroup Study. Int J Clin Oncol. 2011 Nov 30 [Epub ahead of print]

22. Polyzos A, Kosmas C, Toufexi H, Malamos N, Lagadas A, Kosmidis C, Ginopoulos P, Ziras N, Kandilis K, Georgoulias V (2005) Docetaxel in combination with irinotecan (CPT-11) in platinum-resistant paclitaxel-pretreated ovarian cancer. Anticancer Res 25:3559–3564

23. Markman M, Hall J, Spitz D, Weiner S, Carson L, Van Le L, Baker M (2002) Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J Clin Oncol 20:2365–2369

ORIGINAL ARTICLE

# Salvage chemotherapy for recurrent or persistent clear cell carcinoma of the ovary: a single-institution experience for a series of 20 patients

Kiyoshi Yoshino · Takayuki Enomoto ·
Masami Fujita · Yutaka Ueda · Toshihiro Kimura ·
Eiji Kobayashi · Tateki Tsutsui · Tadashi Kimura

## Abstract

*Background* Recurrent or persistent clear cell carcinoma (CCC) of the ovary is particularly chemotherapy resistant. The purpose of this study was to review our extensive institutional experiences with recurrent or persistent CCC with the aim of finding a more effective chemotherapy regimen.

*Methods* The medical records of 67 patients treated for CCC of the ovary were retrospectively reviewed to select patients subsequently treated for recurrence or persistence of the disease.

*Results* The review identified 20 patients treated for recurrent or persistent CCC. For these 20 patients, 9 chemotherapeutic regimens, with 125 cycles, were administered. Gemcitabine monotherapy showed the best response rate [1 partial response (20%) and 2 stable diseases out of 5 patients so treated]. A partial response was observed with a combination of docetaxel plus irinotecan in 1 of 11 patients (9%). Stable disease was observed in 1 of 9 cases on a paclitaxel/carboplatin doublet and in 1 case on a docetaxel/carboplatin doublet. The median overall survival time was 8 months (range, 2–52). One group of patients who received gemcitabine therapy showed significantly better survival ($n = 5$, median 18 months) compared with a group who did not ($n = 15$, median 7 months) ($P = 0.0108$, by univariate analysis). In addition, multivariate Cox proportional hazards analysis revealed that gemcitabine administration was a significant factor for survival (hazard ratio: 13.0, 95% CI: 1.4727–115.2255, $P = 0.02$).

*Conclusion* Although most chemotherapeutic regimens for recurrent or persistent CCC have little or no effect, gemcitabine showed modest activity and is the most effective agent we have tested to date.

**Keywords** Chemotherapy · Clear cell carcinoma · Gemcitabine · Ovarian cancer · Persistence · Recurrence

## Introduction

Epithelial ovarian cancer (EOC) is the second most lethal of the gynecological malignancies (after cervical cancer), causing approximately 125,000 deaths annually worldwide [1]. Standard therapy for EOC includes maximal surgical debulking followed by chemotherapy with platinum and taxane drugs. Despite an initial response rate to this primary therapy of approximately 80%, most EOC patients suffer subsequent recurrence and mortality.

Clear cell carcinoma (CCC) is a subtype of EOC that is relatively uncommon in western countries, including the USA, where CCC comprises only 5–10% of ovarian tumors. In contrast, in Japan, CCC has a higher incidence rate, at 20–25% of all EOCs. The reason behind this significantly higher incidence is not yet fully understood [2].

CCC has distinct biological activities relative to other histological types of ovarian cancer. Sugiyama et al. [3] have reviewed the distinct chemo-resistance and poorer prognosis of CCC. Enomoto et al. [4] showed that this problem continues, even with our best current standard regimen of a paclitaxel/carboplatin doublet.

For recurrent EOC, the treatment strategy depends on the tumor's response to the primary chemotherapy. When

K. Yoshino (✉) · T. Enomoto · M. Fujita · Y. Ueda ·
T. Kimura · E. Kobayashi · T. Tsutsui · T. Kimura
Department of Obstetrics and Gynecology, Osaka University,
Graduate School of Medicine, 2-2 Yamadaoka,
Suita, Osaka 565-0871, Japan
e-mail: yoshino@gyne.med.osaka-u.ac.jp

Ⓐ Springer

recurrence occurs more than 12 months after the completion of the initial therapy, re-administration of the same chemotherapy can be effective in many cases, resulting in extended survival times. However, if the recurrence occurs before 6 months have passed, most chemotherapeutic agents are usually no longer effective [5, 6].

Recurrences of the CCC subtype of EOC tend to be highly chemoresistant to any previous chemotherapy regimen, no matter when they reoccur. Some medical groups have attempted to overcome this resistance by a number of different strategies. Irinotecan (CPT-11) combined with cisplatin (CPT-P) was introduced as an efficacious regimen for refractory or recurrent general EOC, and has been used specifically for CCC. A retrospective Japanese multi-center study reported that a CPT-P group showed significantly better progression-free survival than a group receiving standard TP (taxane plus platinum) [7]. In another strategy, postoperative whole-abdominal radiotherapy (WAR) was carried out. The 5-year overall and disease-free survival in the WAR group was significantly better than that for the standard platinum-based chemotherapy group. However, the adverse effects in the bowel were occasionally severe, causing some patients to require surgery [8].

Clinical trials using novel agents specifically for CCC are ongoing. For persistent or recurrent disease, sunitinib is being evaluated in a phase II study by GOG (NCT 00979992, http://www.clinicaltrials.gov). Another phase II study is evaluating temsirolimus in combination with a paclitaxel/carboplatin doublet followed by temsirolimus consolidation as a first-line therapy in the treatment of stage III–IV CCC (NCT 01196429, http://www.clinicaltrials.gov). The results of these studies should give us a clue as to how to overcome CCC.

In this review, we recount our past experiences with recurrent and persistent CCC, seeking clues for overcoming the scourge that is CCC of the ovary.

## Patients and methods

During the period of 1998–2009, 67 cases of CCC of the ovary (all of Japanese descent) underwent cytoreductive surgery within the Department of Obstetrics and Gynecology at the Osaka University Hospital, Osaka, Japan. The medical records of the patients were reviewed, revealing that the FIGO (International Federation of Gynecology and Obstetrics) staging of these cases was distributed as follows: stage I in 46 cases (Ia; 16 cases, Ib; 1 case, and Ic; 29 cases), stage II in 5 cases (IIc for all), stage III in 14 cases (IIIb; 3 cases, and IIIc; 11 cases), and stage IV in 2 cases.

Study inclusion eligibility criteria for those patients who were treated for recurrent or persistent disease included the following: (1) pathological diagnosis of CCC of the ovary

at the initial surgery, (2) subsequent measurable recurrent or persistent disease, (3) treatment for the recurrent or persistent disease with one or more systemic chemoregimens, and (4) availability of adequate clinical information. The following patient information was abstracted from their medical records: age; date of primary surgery; residual disease; stage of disease based on FIGO criteria; date of completion of the primary chemotherapy; date of first detected recurrence or progression; regimens of each systemic agent administered; date of start and completion of each treatment; number of cycles of each systemic agent; response to each systemic agent administered; status at the last patient contact; and the date of last contact or death. Responses to the systemic agents were recorded according to version 1.0 of the Response Evaluation Criteria in Solid Tumors (RECIST) criteria.

Statistical analyses were performed using MedCalc for Windows (version 11.3.3.0, MedCalc Software, Mariakerke, Belgium). Treatment-free interval (TFI) was defined as the time (months) from the completion of initial therapy to recurrence with a radiological confirmation. For recurrent disease, overall survival time (OS) was calculated from the date of first recurrence to either the date of death or date of last contact. For persistent disease, OS was calculated from the date of primary surgery to either the date of death or date of last contact. A multivariate Cox proportional hazards analysis with selected variables was used to determine the significantly important factors for survivals. The Kaplan–Meier statistical method was used to calculate the overall survival times. Statistical significance was analyzed by the log-rank test. We considered the results to be significant when the $P$ value was less than 0.05.

## Results

After reviewing the medical records of 67 patients with CCC of the ovary, 21 patients were identified as having subsequently had a recurrence or a persistent disease. Of these 21 patients, 1 patient refused to receive any systemic agents and was therefore excluded from this study. A total of 20 patients received systemic agents, thereby meeting the eligibility requirements for this study, and were subsequently analyzed.

The characteristics of these 20 patients are shown in Table 1. The median age was 53 years; ages ranged from 35 to 65. In stage I patients, recurrence occurred in 4 cases with stage Ic (recurrence rate 9% for stage I overall, 14% specifically for stage Ic). There was also a single case of stage IIc, which thus showed a recurrence of 20%. Thirteen of 14 cases (93%) with stage III showed recurrence or persistent disease. Both cases with stage IV had persistent

disease (100%). Ten of the patients were known to still have residual disease after the initial debulking surgery (50%); the remaining 10 patients were classified as having had recurrent disease (50%). Retroperitoneal (pelvic and para-aortic) lymphadenectomy was performed in 12 cases in their initial surgeries (60%).

In our hospital, until 2003, postoperative chemotherapy with paclitaxel/carboplatin doublet (TC) was administered as the standard regimen for all EOC, regardless of histological subtype. Five of our 20-patient pool underwent this

**Table 1** Characteristics of patients with recurrent or persistent clear cell carcinoma of the ovary

| Characteristics | $n = 20$ | % |
| --- | --- | --- |
| Age | | |
|   Median | 53 | |
|   Range | 35–65 | |
| FIGO stage | | |
|   I | 4 | 20 |
|   II | 1 | 5 |
|   III | 13 | 65 |
|   IV | 2 | 10 |
| Residual disease | | |
|   No | 10 | 50 |
|   Yes | 10 | 50 |
| Postoperative chemotherapy | | |
|   None | 1 | 5 |
|   Paclitaxel/Carboplatin | 5 | 25 |
|   Docetaxel/Irinotecan | 14 | 70 |
| Disease status | | |
|   Recurrence | 10 | |
|     TFI: <6 months | 4 | 20 |
|     TFI: ≥6 months | 6 | 30 |
|   Persistent disease | 10 | 50 |

*FIGO* International Federation of Gynecology and Obstetrics, *TFI* treatment-free interval

regimen. Thereafter, starting in 2003, because of the low response rate of this TC regimen, a docetaxel plus irinotecan (DIr) regimen was used for postoperative chemotherapy for advanced stages of CCC, and of these, 14 study patients received this regimen [4]. Among the 10 patients who had no detectable residual disease after initial surgery, but thereafter showed recurrence, 6 had equal to or more than 6 months of TFI, and the remaining 4 had less than 6 months of TFI.

As shown in Table 2, 9 treatment regimens were administered. Paclitaxel/carboplatin doublet (TC) was administered to 9 patients, with a total of 28 cycles, where 1 cycle consisted of paclitaxel (175 mg/m$^2$) plus carboplatin (AUC = 5) every 3 weeks. A docetaxel/carboplatin doublet (DC) was administered for 1 patient, for a total of 3 cycles, where 1 cycle consisted of docetaxel (70 mg/m$^2$) plus carboplatin (AUC = 5) every 3 weeks. A weekly treatment of a paclitaxel/carboplatin doublet (wTC) was administered to 3 patients, for a total of 8 cycles, where 1 cycle consisted of paclitaxel (80 mg/m$^2$ on days 1, 8 and 15) plus carboplatin (AUC = 2 on days 1, 8, and 15) every 4 weeks. DIr was administered to 11 patients, for a total of 41 cycles, where 1 cycle consisted of docetaxel (30 mg/m$^2$ on days 1 and 8) plus irinotecan (60 mg/m$^2$ on days 1 and 8) every 3 weeks. The single-agent gemcitabine (GEM) was administered to 5 patients, for a total of 18 cycles, where 1 cycle consisted of gemcitabine (800 mg/m$^2$ on days 1, 8, and 15) every 4 weeks. The single-agent carboplatin was administered to 1 patient as a single cycle/ single dose of AUC = 5. Oral etoposide was administered to 1 patient, for a total of 2 cycles, where 1 cycle consisted of oral etoposide (50 mg/day for 21 days) every 4 weeks. Pegylated liposomal doxorubicin (PLD) was administered to 1 patient for 2 cycles. One cycle consisted of PLD (40 mg/m$^2$ on day 1) once every 4 weeks. Wilms' tumor 1 vaccine (WT1) was administered to 2 patients, for a total of 22 cycles, where 1 cycle consisted of intradermal injections of an HLA-A*2402-restricted, modified 9-mer WT1

**Table 2** Regimens and maximum responses for recurrent or persistent clear cell carcinoma of the ovary

| Regimens | No. of patients | Total cycles | Median cycles | No. of maximum responses, duration |
| --- | --- | --- | --- | --- |
| Docetaxel + Irinotecan | 11 | 41 | 3 | 1 PR, 6 m |
| Paclitaxel + Carboplatin | 9 | 28 | 3 | 1 SD, 7 m |
| Gemcitabine | 5 | 18 | 4 | 1 PR, 6 m; 2 SD, 4 and 5 m |
| Paclitaxel + Carboplatin (weekly) | 3 | 8 | 3 | PD |
| WT1 vaccine | 2 | 22 | 6 | PD |
| Docetaxel + Carboplatin | 1 | 3 | 3 | 1 SD, 4 m |
| Carboplatin | 1 | 1 | 1 | PD |
| Pegylated liposomal doxorubicin | 1 | 2 | 2 | PD |
| Oral etoposide | 1 | 2 | 2 | PD |

*PR* partial response, *SD* stable disease, *PD* progressive disease

**Table 3** Details of responders who showed more than stable disease with recurrent or persistent clear cell carcinoma of the ovary

| Case | Age | Stage | Residual tumor (sites) | First-line regimen, cycles | TFI (when recurrent) or response (when persistent) | Second-line regimen, cycles | Response, duration | Third-line regimen, cycles | Response, duration | Fourth-line regimen, cycles | Response, duration | Fifth-line regimen, cycles | Response, duration | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 65 | Ic(2) | No | TC ×6 | TFI; 31 m | DC ×3 | SD, 4 m | | | | | | | DOD |
| 2 | 42 | IIc | Yes (om, msty) | DIr ×6 | PD | wTC ×3 | PD | GEM ×3 | PR, 6 m | | | | | DOD |
| 3 | 54 | IIIb | Yes (om, pnm) | DIr ×6 | PD | TC ×3 | PD | GEM ×10 | SD, 5 m | | | | | DOD |
| 4 | 51 | IIc(2) | No | DIr ×6 | TFI; 7 m | TC ×6 | SD, 7 m | WT1 ×6 | PD | GEM ×4 | SD, 4 m | | | AWD |
| 5 | 56 | IIIc | No | DIr ×6, T ×12 | TFI; 5 m | DIr ×6 | PR, 6 m | | | | | PLD ×2 | PD | AWD |

*Ic(2) and IIc(2)* positive cytology of ascites, *om* omentum, *pnm* peritoneum, *msty* mesentery, *TFI* treatment-free interval (months), *DC* docetaxel + carboplatin, *TC* paclitaxel + carboplatin, *T* paclitaxel (consolidation), *wTC* weekly paclitaxel + carboplatin, *DIr* docetaxel + irinotecan, *GEM* gemcitabine, *WTI* Wilms' tumor 1 vaccine, *PLD* pegylated liposomal doxorubicin, *PR* partial response, *SD* stable disease, *PD* progressive disease, *DOD* dead of disease, *AWD* alive with disease

peptide every week [9]. Dose reduction was performed in response to toxicity to the patient's hematological status.

The majority of these administered regimens did not show significant responsiveness. A few showed some modest clinical activity. For example, gemcitabine represented the best response rate, in 1 of 5 patients (20%) it gave a partial response as a third-line treatment, and in 2 stable diseases it gave a response as a third- or fourth-line treatment. A partial response was also observed with DIr in one of 11 patients (9%) when used as a second-line treatment. Stable disease was observed in 1 of 9 cases treated with TC and in 1 case treated with DC, both as second-line efforts. Details of the responders who showed equal to, or more than, stable disease are shown in Table 3.

The median overall survival time of the recurrent or persistent patients was 8 months (range, 2–52), as shown in Fig. 1. Using univariate analysis, a group of patients who received gemcitabine therapy ($n = 5$) showed significantly better survival (median 18 months) compared with a group who did not receive it ($n = 15$, median 7 months) ($P = 0.0108$). A multivariate Cox proportional hazards analysis with selected variables (age, stage, postoperative chemotherapy, TFI, chemotherapy for recurrence or persistent disease) was used to determine the significantly important factors in survival. The analysis revealed that use of DIr for postoperative chemotherapy ($P = 0.02$) and use of gemcitabine for recurrence or persistent disease ($P = 0.02$) were significant factors in survival, as shown in Table 4.

## Discussion

Clear cell carcinoma (CCC) of the ovary is relatively rare in the USA and Europe; however, its incidence in Japan



**Fig. 1** Kaplan–Meier curve showing overall survival time of 20 patients with recurrent or persistent CCC. The median survival time was 8 months

**Table 4** Multivariate Cox proportional hazards analysis for recurrent or persistent clear cell carcinoma of the ovary

| Variables | Hazard ratio | 95% CI | P value |
|---|---|---|---|
| Age | | | |
| <53 ($n = 9$) | 1 | | 0.18 |
| ≥53 ($n = 11$) | 0.37 | 0.0898–1.6041 | |
| Stage | | | |
| I/II ($n = 5$) | 1 | | 0.18 |
| III/IV ($n = 15$) | 6.16 | 0.4298–88.5383 | |
| Postoperative chemotherapy | | | |
| TC ($n = 5$) | 1 | | 0.02 |
| DIr ($n = 14$) | 0.05 | 0.004–0.5792 | |
| TFI | | | |
| <6 months ($n = 14$) | 5.39 | 0.8834–32.9883 | 0.06 |
| ≥6 months ($n = 6$) | 1 | | |
| Chemotherapy for recurrent or persistent disease | | | |
| DIr administration ($n = 11$) | 1 | | 0.23 |
| Without ($n = 9$) | 2.54 | 0.5407–11.9450 | |
| TC administration ($n = 9$) | 1 | | 0.99 |
| Without ($n = 11$) | 0.99 | 0.2205–4.5342 | |
| Gemcitabine administration ($n = 5$) | 1 | | 0.02 |
| Without ($n = 15$) | 13.0 | 1.4727–115.2255 | |

*TFI* treatment-free interval, *DIr* docetaxel/irinotecan, *TC* paclitaxel/carboplatin

accounts for roughly 20% of all EOC. We treated a total of 67 primary cases of CCC, along with 20 examples of recurrence or persistent CCC disease, during the 10-year study period from 1998 to 2009.

As previous reports have described, we also found that recurrent and persistent CCC was extremely chemoresistant. We noted that among the 9 different chemotherapy regimens we attempted, gemcitabine monotherapy showed the better response rate. Our patients who received gemcitabine therapy showed significantly better survival compared with a group who did not receive it. Furthermore, multivariate Cox proportional hazards analysis revealed that gemcitabine administration was a significant factor for survival (hazard ratio: 13.0, 95% CI: 1.4727–115.2255, $P = 0.02$). Therefore, we propose that gemcitabine may be an active chemotherapeutic agent for recurrent or persistent CCC.

Gemcitabine (2′,2′-difluorodeoxycytidine), a synthetic nucleoside analog of cytidine, has already been demonstrated to be an active agent for various other solid tumors, such as non-small-cell lung, pancreatic, genitourinary, and breast cancers [10]. As described in pioneering work from the Plunkett laboratory, gemcitabine is a prodrug that is metabolized to gemcitabine diphosphate and triphosphate, whose incorporation into DNA results in chain termination by inhibiting DNA polymerase activity [11]. Consequently, tumor cells are blocked in the G1 phase of the cell cycle. Gemcitabine triphosphate metabolite can be also incorporated into RNA, thus inhibiting RNA production [12].

Gemcitabine was studied for the first time as a single-agent treatment for recurrent EOC at a dose of 800 mg/m$^2$

on days 1, 8, and 15 every 28 days, thereafter, in a population of platinum-resistant ovarian cancers that included all histological subtypes [13]. In a review by Lorusso et al. [14], the results from a total of 411 patients treated by the single-agent gemcitabine were combined from 12 reports. The combined and re-analyzed data showed a mean gemcitabine response rate of 19%.

Recently, several large randomized control studies have been performed using gemcitabine in ovarian cancer patients. Mutch et al. have shown the safety and efficacy of gemcitabine monotherapy compared with PLD in their phase III trial in patients with platinum-resistant (Pt-R) recurrent ovarian cancer. In their report, gemcitabine and PLD seem to have comparable therapeutic indices, indicating that single-agent gemcitabine may be an acceptable alternative to PLD for patients with Pt-R recurrent disease [15]. For platinum-sensitive (Pt-S) recurrent disease, Pfisterer et al. reported that the addition of gemcitabine to carboplatin significantly improved progression-free survival and response rate compared with carboplatin alone without worsening quality of life in their phase III study [16]. Thus, gemcitabine is recognized as an active agent for both Pt-R and Pt-S recurrent ovarian cancer.

In most reports, gemcitabine's adverse effects and toxicity were easily manageable, transitory, noncumulative, and rarely represented a cause for dose reduction or treatment interruption. Gemcitabine has a well-proven activity in platinum and/or paclitaxel-resistant ovarian cancer patients, and seems to cause no cross-resistance with platinum compounds. However, it should be noted that

most of these studies represented treatments for mainly serous adenocarcinomas, with CCCs accounting for less than 5% of the cases. Therefore, the efficacy of gemcitabine for CCC is still largely unknown.

There are reports which suggest that gemcitabine may have a beneficial clinically active effect for CCC. Crotzer et al. [17] analyzed 51 patients treated for recurrent CCC. Their series received a total of 105 regimens with 344 cycles. In the platinum-sensitive setting, a partial response was observed in only 9% of cases, much lower than the response rates of 50–90% reported for platinum-sensitive disease in all cell types of EOC combined [18]. Among patients with platinum-resistant disease, only 1 patient had a partial response to gemcitabine and 1 patient had stable disease in response to 2 different regimens, paclitaxel and gemcitabine. Generally, second-line chemotherapy for platinum-resistant disease gives response rates of 15–20% when using an active agent.

Komiyama et al. [19] reported successful control with gemcitabine of a single case of peritonitis carcinomatosa presenting with massive ascites in a patient with a heavily pretreated recurrent CCC. Ferrandina et al. described a case of multi-drug-resistant CCC of the ovary showing a selective susceptibility to gemcitabine at first administration and again at re-challenge. Moreover, they showed that the tumor expressed a certain molecular profile that likely made it highly sensitive to gemcitabine [20]. Their finding points out that, although most reports of chemotherapy for CCC are highly disappointing, case-by-case molecular targeting therapy may be the key to combating this difficult to treat disease.

In conclusion, gemcitabine may be a key chemotherapeutic agent for the treatment of aggressive CCCs of the ovary. Additional adjunct molecular targeting therapy should also be considered.

**Conflict of interest** The authors declare that there are no potential conflicts of interest.

# References

1. Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108
2. Ushijima K (2009) Current status of gynecologic cancer in Japan. J Gynecol Oncol 20:67–71
3. Sugiyama T, Kamura T, Kigawa J et al (2000) Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 88:2584–2589
4. Enomoto T, Kuragaki C, Yamasaki M et al (2003) Is clear cell carcinoma and mucinous carcinoma of the ovary sensitive to combination chemotherapy with paclitaxel and carboplatin? Proc Am Soc Clin Oncol 22:447
5. Markman M, Rothman R, Hakes T et al (1991) Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9:389–393
6. Harries M, Gore M (2002) Part II: chemotherapy for epithelial ovarian cancer—treatment of recurrent disease. Lancet Oncol 3:537–545
7. Takano M, Kikuchi Y, Yaegashi N et al (2006) Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary. Oncol Rep 16:1301–1306
8. Nagai Y, Inamine M, Hirakawa M et al (2007) Postoperative whole abdominal radiotherapy in clear cell adenocarcinoma of the ovary. Gynecol Oncol 107:469–473
9. Ohno S, Kyo S, Myojo S et al (2009) Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy. Anticancer Res 29:4779–4784
10. Ozols RF (2001) The current role of gemcitabine in ovarian cancer. Semin Oncol 28:18–24
11. Plunkett W, Huang P, Searcy CE et al (1996) Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol 23:3–15
12. Mackey JR, Mani RS, Selner M et al (1998) Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 58:4349–4357
13. Lund B, Hansen OP, Theilade K et al (1994) Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 86:1530–1533
14. Lorusso D, Ferrandina G, Fruscella E et al (2005) Gemcitabine in epithelial ovarian cancer treatment: current role and future perspectives. Int J Gynecol Cancer 15:1002–1013
15. Mutch DG, Orlando M, Goss T et al (2007) Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 25:2811–2818
16. Pfisterer J, Plante M, Vergote I et al (2006) Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24:4699–4707
17. Crotzer DR, Sun CC, Coleman RL et al (2007) Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol 105:404–408
18. Parmar MK, Ledermann JA, Colombo N et al (2003) Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361:2099–2106
19. Komiyama S, Nakamura M, Murakami I et al (2008) A heavily pretreated patient with recurrent clear cell adenocarcinoma of the ovary in whom carcinomatous peritonitis was controlled successfully by salvage therapy with gemcitabine. Arch Gynecol Obstet 278:565–568
20. Ferrandina G, Legge F, Mey V et al (2007) A case of drug resistant clear cell ovarian cancer showing responsiveness to gemcitabine at first administration and at re-challenge. Cancer Chemother Pharmacol 60:459–461

ORIGINAL PAPER

# WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies: a phase II trial

Takashi Miyatake · Yutaka Ueda · Akiko Morimoto · Takayuki Enomoto ·
Sumiyuki Nishida · Toshiaki Shirakata · Yoshihiro Oka · Akihiro Tsuboi ·
Yusuke Oji · Naoki Hosen · Shin-ichi Nakatsuka · Satoshi Morita ·
Junichi Sakamoto · Haruo Sugiyama · Tadashi Kimura

## Abstract

*Objective* The aim of the present study was to analyze the long-term survival effects of WT1 peptide vaccine, in addition to its anti-tumor effects and toxicity.

*Methods* A phase II clinical trial was conducted during the period of 2004–2010 at Osaka University Hospital, Osaka, Japan. The patients who had gynecologic malignancies progressing against previous treatments received WT1 peptide vaccine intradermally at 1-week intervals for 12 weeks. The vaccination was allowed to further continue, unless the patient's condition became significantly worse due to the disease progression.

*Results* Forty out of 42 patients, who met all the inclusion criteria, underwent WT1 peptide vaccine. Among these 40 patients, stable disease was observed in 16 cases (40 %). Skin toxicity of a grade 1, 2 and 3 occurred in 25 cases (63 %), 9 cases (23 %) and a single case (3 %), respectively, and liver toxicity of grade 1 in a single case (3 %). The overall survival period was significantly longer in cases positive for the WT1 peptide-specific delayed-type hypersensitivity (DTH) reaction after the vaccination, compared to those negative for the DTH reaction ($p = 0.023$). Multivariate Cox proportional hazards analysis demonstrated that the adjusted hazard ratio for the

T. Miyatake · Y. Ueda (✉) · A. Morimoto · T. Enomoto ·
T. Kimura
Department of Obstetrics and Gynecology,
Osaka University Graduate School of Medicine,
2-2, Yamadaoka, Suita, Osaka 565-0871, Japan
e-mail: ZVF03563@nifty.ne.jp

S. Nishida · A. Tsuboi · Y. Oji
Department of Cancer Immunotherapy,
Osaka University Graduate School of Medicine,
2-2, Yamadaoka, Suita, Osaka 565-0871, Japan

T. Shirakata
Department of Biomedical Informatics,
Osaka University Graduate School of Medicine,
2-2, Yamadaoka, Suita, Osaka 565-0871, Japan

Y. Oka
Department of Respiratory Medicine, Allergy and Rheumatic
Diseases, Osaka University Graduate School of Medicine,
2-2, Yamadaoka, Suita, Osaka 565-0871, Japan

Y. Oka
Department of Immunopathology WPI Immunology Frontier
Research Center, Osaka University, 2-2, Yamadaoka,
Suita, Osaka 565-0871, Japan

N. Hosen
Department of Cancer Stem Cell Biology, Osaka University
Graduate School of Medicine, 2-2, Yamadaoka,
Suita, Osaka 565-0871, Japan

S. Nakatsuka
Department of Pathology, Kansai Rosai Hospital,
69-1-3 Inabasou, Amagasaki, Hyogo 660-8511, Japan

S. Morita
Department of Clinical Statistics, Yokohama City University
Medical Center, 4-57, Minami-ku Urabune-cho, Yokohama,
Kanagawa 232-0024, Japan

J. Sakamoto
Department of Health and Community Medicine,
Nagoya University Graduate School of Medicine,
65, Showa-ku Tsurumai-cho, Nagoya,
Aichi 466-8550, Japan

H. Sugiyama
Department of Functional Diagnostic Science, Osaka University
Graduate School of Medicine, 2-2, Yamadaoka,
Suita, Osaka 565-0871, Japan

🖄 Springer

negative DTH reaction was 2.73 (95 % CI 1.04–7.19, $p = 0.043$).

*Conclusion* WT1 peptide vaccine may be a potential treatment, with limited toxicity, for gynecologic malignancies that have become resistant to conventional therapies. Larger scale of clinical studies is required to establish the efficacy of the WT1 peptide vaccine for gynecologic malignancies.

**Keywords** WT1 peptide immunotherapy · Gynecologic malignancy · Anti-tumor effect · Survival · Stable disease · Toxicity

**Abbreviations**

| | |
|---|---|
| CR | Complete response |
| CT | Computed tomography |
| HLA | Human leukocyte antigen |
| HPV | Human papillomavirus |
| OS | Overall survival |
| PD | Progressive disease |
| PFS | Progression-free survival |
| PR | Partial response |
| PS | Performance status |
| RECIST | Response evaluation criteria in solid tumor |
| RR | Responsive rate |
| SD | Stable disease |
| TC | Paclitaxel and carboplatin |

## Introduction

The Wilms tumor gene, *WT1*, was first identified as a tumor suppressor gene responsible for Wilms tumors of the kidney. However, a series of investigations demonstrated that *WT1* possesses an oncogenic, rather than a tumor-suppressive, function, and WT1 protein is expressed in various kinds of hematological and solid malignancies, indicating that immunotherapy targeting WT1 could potentially be used for treatment of a variety of such malignancies (Oka and Sugiyama 2010). In fact, WT1 has been regarded as one of the most promising target antigens for cancer immunotherapy by an American National Cancer Institute pilot project (Cheever et al. 2009). It has already been demonstrated that WT1 vaccination is safe, and encouraging reports that showed its efficacy for several kinds of tumors have been accumulated (Oka and Sugiyama 2010; Hashii et al. 2010; Oji et al. 2010; Izumoto et al. 2008). A previous phase I study empirically determined a safe dose of the WT1 peptide, which was intradermally injected with Montanide ISA 51 adjuvant for patients with solid tumors, as 3 mg per injection, and this dose was shown to have little toxicity except skin reaction of the vaccination sites (Morita et al. 2006).

Ovarian carcinoma accounts for 5 % of all cancers among women and will eventually develop in 1 of every 58 women. It has an extremely high mortality rate; consequently, aggressive cytoreductive surgery followed by chemotherapy with taxane and platinum is the gold standard for its therapy. Endometrial carcinoma is an even more common malignant neoplasm of the female pelvis and is the fourth most common cancer of women today. Endometrial carcinoma is usually confined to the uterus or pelvis, has a lower mortality rate than ovarian cancer and is commonly treated by resection of the uterus and adnexae, with or without co-resection of the regional lymph nodes. Another common gynecological tumor, uterine cervical carcinoma, is mostly associated with a human papilloma virus (HPV) infection, and its incidence appears to vary from one locality to another. It is important to note that in some Asian and South American countries, cervical carcinoma accounts for the largest percentage of cancer deaths in women. Cervical carcinoma is usually treated by radical surgery and/or radiation therapy. And lastly, yet another kind of uterine tumor, the leiomyosarcoma, although rare, has an extremely poor prognosis (DiSaia and Creasman 2002).

Tumors in the early stage of all these diseases are usually treated relatively successfully, while the advanced and recurrent forms of these diseases are often very difficult to treat. Salvage, second-line and third-line chemotherapies are effective in only a fraction of the cases, and the best available supportive care is usually proposed to the patients whose tumors have become resistant to prior therapies.

An immunotherapeutic approach that is less toxic than available chemotherapies might be a more promising option for those whose gynecologic malignancies continue to progress despite conventional chemotherapy and radiation treatments. A previous small study showed that disease stabilization was achieved in 3 (25 %) of 12 gynecologic malignancies by vaccination with an antigenic WT peptide (Ohno et al. 2009). There is only one case report on the effect of WT1 peptide for the survival elongation in a ovarian cancer case (Dohi et al. 2011). In the present phase II trial, we have analyzed for the first time the long-term survival effect of the WT1 peptide vaccine, as well as its anti-tumor effects, evaluated by the usual response evaluation criteria in solid tumor (RECIST) and toxicity.

## Materials and methods

### Eligibility

This phase II trial was conducted at Osaka University Hospital, Osaka, Japan, during the period of 2004–2010. Major inclusion criteria were as follows: having a gynecologic malignancy progressing despite previous treatments;

WT1 protein expression in the primary or metastatic tumor tissue using anti-WT1 rabbit polyclonal antibody C-19 (Santa Cruz Biotechnology) or anti-WT1 mouse monoclonal antibody 6F-H2 (Dako Cytometry); positive status for human leukocyte antigen (HLA)-A*2402; performance status (PS) of 0–2; and life expectancy >3 months.

## Vaccination schedule

The HLA-A*2402-restricted, 9-mer modified WT1 peptide (amino acids 235–243: CYTWNQMNL) emulsified with Montanide ISA 51 adjuvant, was used for the vaccination, as previously described (Hashii et al. 2010). The dose of WT1 peptide injected was 3 mg per body. The WT1 vaccination was scheduled to be performed intradermally every week for 12 weeks but was allowed to continue even after 12 weeks, unless the patient's condition became significantly worse due to the disease progression.

## Evaluation of the WT1 vaccine effects

The primary endpoints of the WT1 vaccine study were its anti-tumor effect and its toxicity. Computed tomography (CT) was performed every 4 weeks to evaluate tumor size. The anti-tumor effect was evaluated by the RECIST (version 1.1) (Eisenhauer et al. 2009) after the vaccination during 12 weeks. Adverse effects were graded based on the National Cancer Institute's Common Toxicity Criteria (version 2.0). A test for delayed-type hypersensitivity (DTH) reaction specific to the WT1 peptide used for vaccination was performed at week 4 and 8. We regarded the patient as DTH positive, if the DTH reaction of the patient was positive either at week 4 or at week 8.

Secondary endpoints were progression-free survival (PFS) and overall survival (OS). PFS was defined as the period from the date of the start of WT1 vaccination to the date of the radiologic or pathologic relapse, or to the date of the last follow-up. OS was defined as the period from the start of the vaccination to the patient's death or to the date of the last follow-up. OS was analyzed for its association with DTH.

## Cancellation or termination of WT1 vaccination

If grade 3 toxicity was observed, the next injection of the WT1 vaccine was postponed until the toxicity returned to grade 2 or less. The vaccination was permanently terminated if grade 4 toxicity was detected or if a performance status of 3 or worse was observed.

## Statistical analysis

MedCalc (MedCalc Software, Mariakerke, Belgium) was used for statistical analysis. The association between DTH induction and anti-tumor effect, including RECIST evaluation, PFS and OS, was analyzed by Fisher's exact test. OS curves were constructed using the Kaplan–Meier method and evaluated for statistical significance by the log-rank test. Multivariate Cox proportional hazards model (stepwise method) for the factors including age, origin of the disease, histology, evaluation of the previous therapy and number of recurrence was calculated to evaluate whether DTH was a significantly important factor on OS. Results were considered to be significant when the $p$ value was <0.05.

## Statements of ethics

This study was approved by the Institutional Review Board and the Ethics Committee of the Osaka University Hospital. All patients provided written informed consent. (Approval of this analysis: #10302, approved on March 11, 2011).

## Results

### Clinical characteristics of the patients and completion rate of the study schedule

During the study period, 42 patients entered the study. Among these, 2 patients were excluded from the present analysis due to protocol violation. The clinicopathological characteristics of these patients are shown in Table 1. The median age was 56 (35–75). The histological diagnosis was obtained as ovarian carcinoma in 24 cases, cervical carcinoma in 11 cases, uterine sarcoma (leiomyosarcoma and carcinosarcoma) in 5 cases. These patients had already received 1–11 (median: 3) kinds of treatments prior to the WT1 vaccination and were considered to have disease

Table 1 Clinical characteristics of patients enrolled in the phase II study

| Characteristics | |
|---|---|
| Number (cases) | 40 |
| Median age (years) (range) | 56 (35–75) |
| Type of malignancy | |
| Ovarian carcinoma | 24 (60 %) |
| Cervical carcinoma | 11 (28 %) |
| Uterine leiomyosarcoma/carcinosarcoma | 5 (13 %) |
| Performance status | |
| 0 | 35 (88 %) |
| 1 | 4 (10 %) |
| 2 | 1 (3 %) |
| Median number of previous treatment regimens (range) | 3 (1–11) |

resistant to conventional therapies such as chemotherapy and radiotherapy.

Injection of the WT1 vaccine was performed weekly for 1–50 (median: 14.5) times. The 12 injections prescheduled upon entry to this trial were completed in 32 of the 40 cases (80 %). Vaccination was terminated prior to the 12th injection due to progression of the disease including worsening of PS in 8 cases (20 %).

## Anti-tumor effect of the WT1 peptide vaccine evaluated by RECIST

Among the 40 patients who received the WT1 vaccination, neither complete response (CR) nor partial response (PR) was obtained. Encouragingly, however, stable disease (SD) of 3 months or more was observed in 16 cases (40 %), including 10 cases of ovarian carcinoma, 5 cases of cervical carcinoma and a single case of uterine leiomyosarcoma, respectively.

The WT1 peptide-specific DTH reaction appeared after the vaccination in 27 cases (68 %); however, the vaccine's anti-tumor effect evaluated by RECIST was not correlated to the appearance of DTH (data not shown).

## Toxicity of the WT1 vaccination

An adverse effect was observed in 36 cases (90 %): grade 1, 2 and 3 of skin reaction in 25 cases (63 %), 9 cases (23 %) and a single case (3 %), respectively, and grade 1 liver toxicity in a single case (3 %). The skin reactions had definite relationship with WT1 injection because the reactions were observed only in WT1 injected area. The liver toxicity occurred after first injection of WT1, and the relationship between WT1 vaccine and liver toxicity was probable. Postponement of the next injection due to adverse effects occurred in one case with grade 3 of skin reaction. However, termination of the WT1 vaccine injection due to adverse effects was never required.

## Prognosis of the patients treated with WT1 peptide vaccine: the vaccines' survival effect

The PFS was 84 days (11–497). Surprisingly, among these WT1-vaccinated cases, which had been already resistant to conventional therapies and the disease had exhibited continuous progression against various other treatments for 40–1,198 days (median: 185 days), progression-free survival for a range of 67–427 days (median: longer than 160 days) was achieved in 16 SD cases (Table 2). The median OS of all the patients was 193 days (29–941).

Although an association between an anti-tumor effect evaluated RECIST and an appearance of DTH reaction was not observed, the PFS tended to be longer in DTH-positive

**Table 2** Duration of disease progression before WT1 vaccination was begun and progression-free period afterward in stable disease (SD) cases

| Case number | Duration of disease progression before WT1 vaccine (days) | Progression-free survival after WT1 vaccine (days) |
|---|---|---|
| 1 | 40 | 105[a] |
| 2 | 55 | 67 |
| 3 | 61 | 427[a] |
| 4 | 81 | 320 |
| 5 | 97 | 126 |
| 6 | 142 | 145 |
| 7 | 155 | 92 |
| 8 | 178 | 273 |
| 9 | 192 | 140[a] |
| 10 | 324 | 84 |
| 11 | 405 | 175 |
| 12 | 434 | 196 |
| 13 | 439 | 84[a] |
| 14 | 655 | 196 |
| 15 | 737 | 219 |
| 16 | 1,198 | 180[a] |
| Median | 185 | 160[a] |

The duration of disease progression before the WT1 vaccine, and the progression-free period after the start of WT1 vaccination in 16 SD cases, is demonstrated

[a] The cases in which the disease was stable after WT1 vaccination without progression

cases than DTH-negative ones ($p = 0.23$ by the log-rank test), and the OS was significantly longer in DTH-positive cases than DTH-negative ones ($p = 0.023$ by the log-rank test) (Fig. 1).

## Multivariate Cox proportional hazards analysis

We utilized the multivariate Cox proportional hazards model in order to find evidence to further support our belief that the DTH reaction was significantly associated with the survival. The DTH reaction was demonstrated to be an independent factor for overall survival of the patients (Table 3). The adjusted hazard ratio (HR) for the DTH reaction (− vs. +) was 2.73 (95 % CI 1.04–7.19, $p = 0.043$).

## Discussion

A National Cancer Institute pilot project recently suggested that WT1 was one of the most promising targets for cancer immunotherapy (Cheever et al. 2009), and it has been demonstrated that WT1 vaccination is safe and has therapeutic potential for at least several kinds of tumors (Oka and Sugiyama 2010; Hashii et al. 2010; Oji et al. 2010;